<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28645" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rosiglitazone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Quintanilla Rodriguez</surname>
            <given-names>Bryan S.</given-names>
          </name>
          <aff>New York Medical College - Metropolitan Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Correa</surname>
            <given-names>Ricardo</given-names>
          </name>
          <aff>University of Arizona</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bryan Quintanilla Rodriguez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ricardo Correa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28645.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Rosiglitazone is a medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinediones class of medications. This activity reviews the indications, actions, and contraindications for rosiglitazone as a valuable agent in the management of diabetes type 2. This activity will highlight rosiglitazone requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results and prevent complications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of rosiglitazone.</p></list-item><list-item><p>Describe the potential adverse effects of rosiglitazone.</p></list-item><list-item><p>Review the appropriate monitoring and toxicity of rosiglitazone.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication among interprofessional team members to advance rosiglitazone and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28645&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28645">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28645.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rosiglitazone is a drug FDA approved for the treatment of type 2 diabetes mellitus. It belongs to the family called thiazolidinediones. It is capable of lowering the glucose levels by improving target cell response to insulin without increasing the stimulation and release of insulin by the pancreatic beta cells. This drug acts by activating the nuclear peroxisome proliferator-activated (PPAR) receptor gamma; the primary role of this intracellular receptor appears to be regulating adipogenesis along with glucose and metabolism. Rosiglitazone use can be as monotherapy or in combination with other oral hypoglycemic drugs, such as metformin or sulfonylureas. Rosiglitazone is a very potent thiazolidinedione; it has a binding affinity for PPAR-gamma 30-fold higher than pioglitazone.<xref ref-type="bibr" rid="article-28645.r1">[1]</xref></p>
        <p>Currently, there are two thiazolidinediones available: rosiglitazone and pioglitazone. Rosiglitazone carries a low risk of causing hypoglycemia and improves insulin resistance significantly; it has been incorporated into clinical practice and is prescribed by many physicians in selected patients.</p>
        <p>There are reports that thiazolidinediones, including rosiglitazone, typically reduce hemoglobin A1c by 1 to 2% compared to placebo. Its potency to decrease glycemic levels is similar to the hypoglycemic effect of metformin and sulfonylureas. Its effect is mainly by increasing skeletal muscle glucose uptake. It is also considered to preserve pancreatic beta-cell function.</p>
        <p>Thiazolidinediones first appeared for the treatment of type 2 diabetes mellitus in 1996. The first approved drug by the FDA was troglitazone. This drug got pulled from the market because of its idiosyncratic hepatotoxicity. Rosiglitazone was patented in 1987 and approved for medical use in 1999. In 2011 rosiglitazone was restricted given its apparent relationship with increased heart attack risk. In 2013, the FDA removed the restrictions of this drug after a clinical trial failed to show increased heart risk in patients using rosiglitazone.<xref ref-type="bibr" rid="article-28645.r2">[2]</xref></p>
      </sec>
      <sec id="article-28645.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The molecular mechanism of action behind this drug is the binding of nuclear peroxisome proliferator-activated (PPAR) receptor gamma to the PPRE gene inducing the expression of several genetic networks. It increases insulin-stimulated IRS-1/2 in skeletal muscle and adipose tissue, and subsequently, the expression of GLUT4 glucose transporter. Peroxisome proliferator-activated receptor-gamma agonistic effect potentiates insulin signaling and improves insulin sensitivity at various molecular steps by activating PI3K, PIP3, and serine/ threonine kinases. Peroxisome proliferator-activated-gamma activation in adipocyte tissue induces the expression of genes involved in insulin signaling such as GLUT4 glucose&#x000a0;transporter and CAP, thereby improving insulin sensitivity. Finally, PPAR-gamma improves insulin sensitivity by three apparent mechanisms: 1) increases expression of GLUT4 glucose transporter, 2) regulates signaling factors in adipocyte tissue that affect insulin sensitivity in muscle tissue, and 3) inducing the production of more insulin sensitive adipocyte tissue.<xref ref-type="bibr" rid="article-28645.r1">[1]</xref><xref ref-type="bibr" rid="article-28645.r2">[2]</xref></p>
        <p>Rosiglitazone and thiazolidinediones affect the vasculature by decreasing the intimal-medial thickness and the development of atherosclerosis in the vascular smooth muscle cells. The protective effect occurs by inhibiting the gene expression of AT1R, TXS, and TXR, involved with intimal medial thickness and atherosclerosis.<xref ref-type="bibr" rid="article-28645.r1">[1]</xref><xref ref-type="bibr" rid="article-28645.r2">[2]</xref><xref ref-type="bibr" rid="article-28645.r3">[3]</xref><xref ref-type="bibr" rid="article-28645.r4">[4]</xref></p>
        <p>Rosiglitazone bioavailability is high (99%). The onset of action initially is delayed; the maximum effect is achieved up to 12 weeks. It is mostly protein-bound (99%). It is subject to hepatic metabolism and excreted by urine (64%) and feces (22%).<xref ref-type="bibr" rid="article-28645.r2">[2]</xref><xref ref-type="bibr" rid="article-28645.r3">[3]</xref></p>
      </sec>
      <sec id="article-28645.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Rosiglitazone administration is via the oral route. It is available in 2 mg and 4 mg tablets. Its indication is the treatment of type 2 diabetes mellitus. The initial dose is 4 mg orally each day or divided every 12 hours. If the glycemic response is inadequate after 8 to 12 weeks, dosing can increase to 8 mg by mouth each day or divided every 12 hours.<xref ref-type="bibr" rid="article-28645.r5">[5]</xref></p>
        <p>After beginning the drug and&#x000a0;following subsequent dose modifications, patients must be observed for rapid weight gain, dyspnea, and/or edema. If symptoms develop, manage the congestive heart failure according to approved care management.<xref ref-type="bibr" rid="article-28645.r5">[5]</xref></p>
      </sec>
      <sec id="article-28645.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects reported are increased LDL-cholesterol, increased HDL-cholesterol, increased total cholesterol. Less common adverse effects are edema, hypertension, heart failure/congestive heart failure, myocardial ischemia, diarrhea, upper respiratory tract infection. Uncommon adverse effects reported include anemia, back pain, fatigue, headache, hypoglycemia, myalgia, sinusitis, weight gain.</p>
        <p>Reports exist an increased risk of fractures of the upper arm, hand, or foot in women.</p>
        <p>There are case reports of macular edema that have been reported in the literature, as well as cases of ovulation in anovulatory women.<xref ref-type="bibr" rid="article-28645.r6">[6]</xref><xref ref-type="bibr" rid="article-28645.r7">[7]</xref></p>
      </sec>
      <sec id="article-28645.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to rosiglitazone include patients with active liver disease, hypersensitivity, Type 1 diabetes mellitus, diabetic ketoacidosis, and hyperosmolar hyperglycemic state.&#x000a0;</p>
        <p>Strict contraindications to the administration of rosiglitazone include patients with congestive heart failure with New York Heart Association functional class III or IV. Thiazolidinediones, including rosiglitazone, can exacerbate congestive heart failure. After starting this drug, and adjusting the dose, observe patients for signs and symptoms of heart failure (weight gain, edema, dyspnea), which would indicate discontinuation of therapy. Combination with insulin in patients with congestive heart failure functional class I and II may increase the risk of other cardiovascular effects. Peroxisome proliferator-activated (PPAR) gamma agonists can cause fluid retention when used in combination with insulin.</p>
        <p>It has been reported not sufficient data in pregnant women to determine the associated risk for congenital defects and miscarriage.<xref ref-type="bibr" rid="article-28645.r7">[7]</xref><xref ref-type="bibr" rid="article-28645.r8">[8]</xref></p>
      </sec>
      <sec id="article-28645.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring of the liver function test (particularly the ALT) should occur at the beginning of the treatment, then every month for 12 months, and then every three months.&#x000a0;</p>
        <p>In the case of renal impairment, no adjustment in the dose is necessary.</p>
        <p>If rosiglitazone is being co-administrated with sulfonylureas, dosage adjustments and patient monitoring are recommended to avoid hypoglycemic incidents.<xref ref-type="bibr" rid="article-28645.r9">[9]</xref><xref ref-type="bibr" rid="article-28645.r10">[10]</xref></p>
      </sec>
      <sec id="article-28645.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>For patients with impaired liver function test who reports ALT greater than three times the normal upper limit, it is recommended to stop the treatment. In cases of ALT showing 1.5 to 3 times the upper normal limit, it is recommended to re-test every week until normalization of liver function test.<xref ref-type="bibr" rid="article-28645.r11">[11]</xref><xref ref-type="bibr" rid="article-28645.r10">[10]</xref></p>
      </sec>
      <sec id="article-28645.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Primary care physicians, nurse practitioners, internists, and&#x000a0;endocrinologists can all prescribe rosiglitazone. The drug is useful for the treatment of type 2 diabetes mellitus. However, healthcare workers, including the pharmacists, must warn the patient about the contraindications of this medication in patients with congestive heart failure with New York Heart Association functional class III or IV. Rosiglitazone causes exacerbation of congestive heart failure, and the pharmacist, nurse, and clinician work as a team to monitor patients closely for signs and symptoms of heart failure. Discontinuation is the recommended course if symptoms appear. It is recommended to observe liver function tests in patients using this drug, given its potential hepatic damage.<xref ref-type="bibr" rid="article-28645.r11">[11]</xref><xref ref-type="bibr" rid="article-28645.r12">[12]</xref></p>
        <p>Rosiglitazone requires an interprofessional team approach, including clinicians (MDs, DOs, and mid-level practitioners), specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results and prevent complications. [Level 5]</p>
      </sec>
      <sec id="article-28645.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28645&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28645">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28645/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28645">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28645.s11">
        <title>References</title>
        <ref id="article-28645.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Della-Morte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palmirotta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rehni</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pastore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Capuani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pacifici</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Marchis</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Bellia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fogliame</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferroni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Donadel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cacciatore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abete</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pileggi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roselli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ricordi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sbraccia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guadagni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rundek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lauro</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.</article-title>
            <source>Pharmacogenomics</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>16</issue>
            <fpage>2063</fpage>
            <page-range>2063-82</page-range>
            <pub-id pub-id-type="pmid">25521362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauner</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The mode of action of thiazolidinediones.</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2002</year>
            <season>Mar-Apr</season>
            <volume>18 Suppl 2</volume>
            <fpage>S10</fpage>
            <page-range>S10-5</page-range>
            <pub-id pub-id-type="pmid">11921433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubois</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vantyghem</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Schoonjans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pattou</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>6 Pt 1</issue>
            <fpage>511</fpage>
            <page-range>511-23</page-range>
            <pub-id pub-id-type="pmid">12527853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Millioni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Puricelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Iori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arrigoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tessari</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The effects of rosiglitazone and high glucose on protein expression in endothelial cells.</article-title>
            <source>J Proteome Res</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>578</fpage>
            <page-range>578-84</page-range>
            <pub-id pub-id-type="pmid">19911850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebovitz</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Dole</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Patwardhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rappaport</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Freed</surname>
                <given-names>MI</given-names>
              </name>
              <collab>Rosiglitazone Clinical Trials Study Group</collab>
            </person-group>
            <article-title>Rosiglitazone monotherapy is effective in patients with type 2 diabetes.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>280</fpage>
            <page-range>280-8</page-range>
            <pub-id pub-id-type="pmid">11232013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bundhun</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Janoo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Teeluck</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2017</year>
            <month>Oct</month>
            <day>23</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <pub-id pub-id-type="pmid">29058622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Jun</month>
            <day>14</day>
            <volume>356</volume>
            <issue>24</issue>
            <fpage>2457</fpage>
            <page-range>2457-71</page-range>
            <pub-id pub-id-type="pmid">17517853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winterstein</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Rosiglitazone and the risk of adverse cardiovascular outcomes.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>776</fpage>
            <page-range>776-8</page-range>
            <pub-id pub-id-type="pmid">21593751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Rosiglitazone.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>921</fpage>
            <page-range>921-30; discussion 931-2</page-range>
            <pub-id pub-id-type="pmid">10400405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>[Medication of the month. Rosiglitazone (Avandia)].</article-title>
            <source>Rev Med Liege</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>236</fpage>
            <page-range>236-9</page-range>
            <pub-id pub-id-type="pmid">12073798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werner</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Travaglini</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>A review of rosiglitazone in type 2 diabetes mellitus.</article-title>
            <source>Pharmacotherapy</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>1082</fpage>
            <page-range>1082-99</page-range>
            <pub-id pub-id-type="pmid">11560198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28645.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blickl&#x000e9;</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>[Thiazolidinediones: clinical data and perspectives].</article-title>
            <source>Diabetes Metab</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2 Pt 2</issue>
            <fpage>279</fpage>
            <page-range>279-85</page-range>
            <pub-id pub-id-type="pmid">11452222</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
